Chen, Pei-Yu
Qin, Lingfeng
Li, Guangxin
Wang, Zheng
Dahlman, James E.
Malagon-Lopez, Jose
Gujja, Sharvari
Cilfone, Nicholas A.
Kauffman, Kevin J.
Sun, Lele
Sun, Hongye
Zhang, Xinbo
Aryal, Binod
Canfran-Duque, Alberto
Liu, Rebecca
Kusters, Pascal
Sehgal, Alfica
Jiao, Yang
Anderson, Daniel G.
Gulcher, Jeffrey
Fernandez-Hernando, Carlos http://orcid.org/0000-0002-3950-1924
Lutgens, Esther
Schwartz, Martin A.
Pober, Jordan S.
Chittenden, Thomas W.
Tellides, George
Simons, Michael http://orcid.org/0000-0003-0348-7734
Funding for this research was provided by:
National Natural Science Foundation of China (81600365)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL135582)
Article History
Received: 14 January 2019
Accepted: 16 July 2019
First Online: 26 August 2019
Competing interests
: M.S. and P.Y.C. are holders of a provisional US Patent Application 62/311,086 and 62/406,732 dealing with endothelial-specific treatment of atherosclerosis. M.S., P.Y.C. and D.G.A. are scientific founders of VasoRx, Inc. M.S. and D.G.A. are members of VasoRx, Inc. Scientific Advisory Board. The other authors declare no competing interests.